Genetix Pharmaceuticals Closes $35M in Series B Venture Financing

Gene therapy company is developing breakthrough treatments for severe genetic disorders
The Series B financing round was completed with new investors Third Rock Ventures and Genzyme Ventures, and current investors TVM Capital, Forbion and Easton Capital. The company will use the funds to advance clinical programs, team expansion, and strengthen its platform capabilities. According to the corporate press release, “Genetix’s proprietary lentiviral technology delivers corrective genes to the patient’s own bone marrow cells, providing a one-time effective therapy, which is a true paradigm shift in the treatment of genetic diseases.” The company has operations in the US and France.

↑ Back to TechConnect News™

Event Spotlights

DITAC
Austin, TX, December 1-3, 2015
DES
Austin, TX, December 1-3, 2015
 

Annual Meeting

TechConnect World 2015
Washington, DC, May 22-25, 2016